Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 111,695

Document Document Title
WO/2016/062242A1
The present invention provides a peptide capable of promoting neuron growth, particularly a peptide capable of promoting neurite growth, and an application thereof.  
WO/2016/058192A1
A traditional Chinese medicine composition for treating insomnia, and a preparation method for same, the composition being composed of 45-55 parts by weight Radix paeoniae alba, 45-55 parts by weight Semen ziziphi spinosae, 45-55 parts b...  
WO/2016/058537A1
Uses of an achaete-scute complex homolog-like 1 (Ascl1) gene or a protein thereof or an accelerator thereof: (i) use in preparing a pharmaceutical composition for inducing astrocytes to become functional neuron cells; and/or (ii) use in ...  
WO/2016/059162A1
Described herein is the use of CSF, more particularly external CSF or CSF-like compositions for the treatment and prevention of different diseases. More particularly, the application provides for the administration of CSF to the intrathe...  
WO/2016/060190A1
The present invention addresses the problem of providing a therapeutic agent for cognition disorders induced by amyloid β-protein, the therapeutic agent functioning by a mechanism in which amyloid β-protein is involved but which is dif...  
WO/2016/059403A1
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Len...  
WO/2016/059404A1
The present disclosure relatesto the use of cannabidiol (CBD) for the treatment of seizures associated with Aicardi Syndrome. In one embodiment the seizures associated with Aicardi Syndrome are convulsive seizures; focal seizures with im...  
WO/2016/059399A1
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC). In particular the TSC is treatment resistant and is characterised by generalised seizures or focal seizures with impair...  
WO/2016/059307A1
The invention relates to a drug combination comprising gaseous xenon and at least one antagonist of the NMDA receptors in a liquid or solid form for treating a disease caused by a dysfunction of the dopaminergic synaptic transmission in ...  
WO/2016/058071A1
The present invention relates to the method for extracting and isolating active substances from umbu pulp (Spondias tuberosa Arr. Camara). Besides high acetylcholinesterase inhibitory activity, the active substances also exhibit powerful...  
WO/2016/061393A1
Monomethyl and monoethyl fumarate prodrugs, pharmaceutical compositions comprising the monomethyl and monoethyl fumarate prodrugs, and methods of using monomethyl and monoethyl fumarate prodrugs and pharmaceutical compositions for treati...  
WO/2016/059269A1
The invention relates to the methods for producing derivatives of 3-alkylamino-1H-indole acrylate (I) with transcription factor Nrf2-inducing activity, free radical scavenging activity and neuroprotective ability. The invention also rela...  
WO/2016/060111A1
The purpose of the present invention is to provide a method for producing γδT cells with which it is possible to obtain a cell population including a large amount of γδT cells and including virtually no cells infected by human T-cell...  
WO/2016/059412A1
This invention relates to novel compounds of formula (I) wherein 'A' is a 5 or 6 membered heteroaryl group, unsubstituted or substituted with 1, 2 or 3 groups as defined in claim 1; X is a bond or -(CRA1RB1)n-; Y is selected from: a bond...  
WO/2016/060122A1
An adhesive patch which is provided with a supporting body and an adhesive layer that is arranged on at least one surface of the supporting body. The adhesive layer contains at least one substance that is selected from the group consisti...  
WO/2016/056638A1
The present invention provides a pharmaceutical composition which includes: a compound represented by formula (1), or N-[3-((4aS, 5R, 7aS)-2-amino-5-methyl-4a, 5, 7, 7a-tetrahydro-4H-furo[3, 4-d][1, 3]thiazine-7a-yl)-4-fluorophenyl]-5-di...  
WO/2016/055618A1
The present invention provides triazolopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.  
WO/2016/056645A1
In the present invention, an expression vector that promotes lysosome uptake of a target nucleic acid and identifies a protein that induces degradation of an abnormal nucleic acid, or includes the genes encoding the same, has been develo...  
WO/2016/057322A1
Provided herein are deuterated compounds and compositions useful in increasing PPAR5 activity. The compounds and compositions provided herein are useful for the treatment of PPAR5 related diseases (e.g., muscular diseases, vascular disea...  
WO/2016/057789A1
A treatment for pruritus is described that is based upon amylase. The amylases (α-, β-, ϒ-amylase) are noted for the cleavage of the α-glycosidic bonds of polysaccharides, yielding lower molecular weight carbohydrate/sugar fragments....  
WO/2016/057454A1
The present invention relates to the field of Wilson Disease. More specifically, the present invention provides methods and compositions useful for treating Wilson Disease by targeting liver nuclear receptors. In a specific embodiment, a...  
WO/2016/057533A1
The present invention relates to use of very low dose lithium for primary and secondary prevention of dementia-related disorders and suicide.  
WO/2016/057656A1
Provided herein are methods for increasing PPAR5 activity and methods for treating PPARδ related diseases (e.g., mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases, and metabolic diseases).  
WO/2016/056689A1
The present invention relates to a method for proliferating neural progenitor cells and a composition for treating nerve disorders containing proliferated neural progenitor cells. It was verified that, when fetal neural progenitor cells ...  
WO/2016/057658A8
Provided herein are compounds of Formula (I) and compositions useful in increasing PPARS activity. The compounds and compositions provided herein are useful for the treatment of PPARS related diseases (e.g., muscular diseases, vascular d...  
WO/2016/057713A1
Methods for treating a subject suffering from a sterol synthesis disorder or a sterol deficiency disorder, e.g., Smith-Lemli-Opitz syndrome, the method comprising administering to the subject an effective amount of an NMDA receptor modul...  
WO/2016/055517A1
The present invention relates to a compound for use in the treatment and/or prevention of diseases or disorders wherein an inhibition of protein prenylation is required, which is alternatively chosen, among formulae (I) and (II), wherein...  
WO/2016/055482A1
The present invention relates to isoindoline derivatives according to formula (I), which are Positive Allosteric Modulators of D1 and accordingly of benefit as pharmaceutical agents for the treatment of diseases in which D1 receptors pla...  
WO/2016/056520A1
 Provided are a feed for aquatic animals and a growth promoter for aquatic animals that result in the healthy growth of fish and impart strong recovery capabilities thereto, even when water temperatures are substantially higher than no...  
WO/2016/055496A1
The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the pres...  
WO/2016/055858A1
The present application relates to compounds of formula (I), (la), or (lb) and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing Αβ-related pathologies such as Down's ...  
WO/2016/055160A3
The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encodi...  
WO/2016/057658A1
Provided herein are compounds of Formula (I) and compositions useful in increasing PPARS activity. The compounds and compositions provided herein are useful for the treatment of PPARS related diseases (e.g., muscular diseases, vascular d...  
WO/2016/051024A1
The present invention relates to pounds of general formula (I) and pharmaceutically acceptable salts thereof; wherein R1 - R11, L, Z, Y, and Z are as defined in the claims. The invention also relates to said compounds for use as a medica...  
WO/2016/052656A1
An autophagy inducing agent that comprises at least one member selected from a compound represented by structural formula (A), a compound represented by structural formula (B), and a compound represented by structural formula (C).  
WO/2016/051155A1
A compound of the general formula A or a or a pharmaceutically acceptable salt or solvate thereof, wherein: R1 is selected from the group consisting of: C1-C12-alkyl, C3-C12-cycloalkyl, C6- C10-aryl, and C5-C7-heteroaryl; each optionally...  
WO/2016/051420A1
The invention relates to the compounds of formula II or their pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The invention further relates to pharmaceutical compositions...  
WO/2016/053947A1
Disclosed is a crystalline polymorph 1-(1-methyl-1H-pyrazol-4-yl)-N-((1R,5S,7S)- 9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1H-indole-3-ca rboxamide, Form G, and processes for making the same  
WO/2016/053794A1
The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.  
WO/2016/049884A1
Provided are a conotoxin polypeptide κ-CPTx-bt105, a method for preparation thereof, and an application thereof. The conotoxin polypeptide consists of 16 amino acids, has a molecular weight of 1626.62 daltons, and has the full sequence ...  
WO/2016/051196A1
The present invention is directed to the treatment of paroxysmal extreme pain disorder (PEPD) comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)- prolina...  
WO/2016/049864A1
Disclosed are a conotoxin polypeptide κ-CPTx-bt101, a method for preparation thereof, and an application thereof. The conotoxin polypeptide of the present invention consists of 18 amino acids, has a molecular weight of 1872.72 daltons, ...  
WO/2016/050975A1
A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders...  
WO/2016/051194A1
The present invention is directed to the treatment of erythromelalgiacomprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4- {[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamideor a pharmaceutically...  
WO/2016/049700A1
The present invention relates generally to intranasal pharmaceutical compositions. In particular, the present invention is directed to sustained, enhanced delivery of pharmaceutical agents across the nasal mucosa for systemic drug delivery.  
WO/2016/054432A1
The present invention is directed to copolypeptide hydrogels (DCH) containing non-ionic hydrophilic residues (DCHEO ), incorporation of thermoresponsive elements into DCHEO, to generate thermoresponsive DCH (DCHT), and hydrogels that inc...  
WO/2016/049881A1
Provided are a conotoxin polypeptide κ-CPTx-bt104, a method for preparation thereof, and an application thereof. The conotoxin polypeptide consists of 11 amino acids, has a molecular weight of 1313.47 daltons, and has the full sequence ...  
WO/2016/049873A1
Provided are a conotoxin polypeptide κ-CPTx-bt103, a method for preparation thereof, and an application thereof. The conotoxin polypeptide consists of 29 amino acids, has a molecular weight of 3141.43 daltons, and has the full sequence ...  
WO/2016/052617A1
The present invention addresses the problem of providing a nalfurafine-containing preparation for topical application that has high drug stability in the preparation and excellent drug transfer properties from the preparation to a living...  
WO/2016/050160A1
Provided is a paliperidone oral controlled-release tablet, comprising: a single-layer tablet core containing paliperidone, a first coating layer and a second coating layer coating the single-layer tablet core to control release of medica...  

Matches 301 - 350 out of 111,695